Healthcare
Live Price
Offline$59.24
-2.24% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Becton, Dickinson and Company (BDXA) is a Healthcare stock with a market cap of $55.91B. The stock last traded around $59.24. Baseline metrics include revenue growth of +8.2%, EPS growth of -0.7%, a dividend yield of 2.6%. What stands out right now is revenue +8.2%, EPS -0.7%, free cash flow -13.1% with operating margin 12.4% and ROIC 4.8%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 23.4 and price/sales 2.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BDXA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BDXA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BDXA Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BDXA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$19.1B
+1.4% YoY
FY Net Income
$2.1B
+17.6% YoY
Free Cash Flow
$3.4B
+105.8% YoY
Revenue Growth
+8.2%
EPS Growth
-0.7%
Gross Margin
45.8%
Net Margin
8.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21.8B | 20.2B | 19.4B | 18.9B | 19.1B |
| Gross Profit | 9.9B | 9.1B | 8.2B | 8.5B | 8.6B |
| Operating Income | 2.6B | 2.4B | 2.1B | 2.3B | 2.3B |
| EBITDA | 5.0B | 4.8B | 4.4B | 4.4B | 4.4B |
| Net Income | 1.7B | 1.7B | 1.5B | 1.8B | 2.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 851M | 1.9B | 1.4B | 1.2B | 2.4B |
| Total Assets | 55.3B | 57.3B | 52.8B | 52.9B | 53.9B |
| Total Liabilities | 29.9B | 31.4B | 27.0B | 27.7B | 30.2B |
| Shareholder Equity | 25.4B | 25.9B | 25.8B | 25.3B | 23.7B |
| Total Debt | 19.2B | 21.6B | 16.8B | 17.0B | 18.4B |
| Net Debt | 18.3B | 19.7B | 15.3B | 15.8B | 16.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4.6B
+76.5% YoY
Capital Expenditures
1.2B
-26.5% YoY
Free Cash Flow
3.4B
+105.8% YoY
Key ratios
Gross Margin
45.8%
Operating Margin
12.4%
Net Margin
8.0%
ROE
6.9%
Debt / Equity
0.77x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.